BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) Stock Analysis
DELISTED 2022
What happened to BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) stock?
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) no longer trades on public markets. It was delisted in March 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) trades at $0.04. BioDelivery Sciences Intl, Inc. Wrrt operates within the healthcare sector, focusing on drug manufacturing. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for BDSIW: BDSIW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BDSIW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
BDSIW: 2/2 scored disciplines lean bullish. Dominant signal: Moon AI bullish.
How is this calculated? →BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) Healthcare & Pipeline Overview
BioDelivery Sciences Intl, Inc. Wrrt is a pharmaceutical company specializing in drug development and commercialization within the general drug manufacturing sector. With a high gross margin of 86.0% and a profit margin of 50.9%, the company showcases strong profitability, balanced by a high beta of 17.76, reflecting significant market sensitivity.
What Is the Investment Thesis for BDSIW?
BioDelivery Sciences Intl, Inc. Wrrt presents a compelling investment case based on its high gross and profit margins, indicating efficient operations and strong pricing power. The company's focus on specialty pharmaceuticals and innovative drug delivery technologies positions it well within a growing market. However, the extremely high beta of 17.76 suggests significant volatility and sensitivity to market fluctuations, which could impact investor returns. Key value drivers include successful commercialization of existing products and the development of new pipeline assets. Growth catalysts include potential partnerships, regulatory approvals, and expansion into new therapeutic areas. Investors should carefully consider the company's high beta and dependence on successful product development and commercialization.
Based on FMP financials and quantitative analysis
BDSIW Key Highlights
Gross Margin of 86.0% indicates strong pricing power and efficient cost management.
- Profit Margin of 50.9% demonstrates high profitability relative to revenue.
- P/E Ratio of 6.8 suggests the company may be undervalued compared to its earnings.
- Focus on specialty pharmaceuticals provides access to higher-margin products.
- Innovative drug delivery technologies differentiate the company from competitors.
Who Are BDSIW's Competitors?
BDSIW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1245.69 | -2.71% | $1.17T | 97 |
| BMYMP Bristol-Myers Squibb Company PFD CONV 2 | $400.00 | -57.46% | $815B | 50 |
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| ABBV AbbVie Inc. | $265.06 | -0.34% | $468B | 82 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| RHHBY Roche Holding AG | $58.24 | +4.90% | $371B | 61 |
| RHHBF Roche Holding AG | $465.00 | +5.68% | $371B | 54 |
| RHHVF Roche Holding AG | $458.51 | -1.27% | $316B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BDSIW's Key Strengths?
Innovative drug delivery technologies.
- High gross and profit margins.
- Focus on specialty pharmaceuticals.
- Established commercial infrastructure.
What Are BDSIW's Weaknesses?
High beta indicates significant market volatility.
- Dependence on successful product development and commercialization.
- Limited geographic reach.
- Small market capitalization.
What Could Drive BDSIW Stock Higher?
Potential regulatory approvals for new products in the pipeline.
- Continued commercialization and market penetration of existing products.
- Strategic partnerships and collaborations to expand market reach.
What Are the Key Risks for BDSIW?
Negative return on equity (-30.8%) — the business is not currently generating profit on shareholder capital.
- Insider selling — insiders were net sellers of roughly $2.9M recently.
- Failure to obtain regulatory approvals for new products.
- Competition from generic drugs and biosimilars.
- High beta indicates significant market volatility.
- Product liability claims and litigation.
What Are the Growth Opportunities for BDSIW?
- Expansion into new therapeutic areas: BioDelivery Sciences can leverage its drug delivery technologies to develop products for new therapeutic areas beyond pain management. This diversification strategy could significantly expand the company's addressable market and reduce its dependence on a single product or indication. The market for specialty pharmaceuticals is growing rapidly, driven by unmet needs and advancements in medical science. Successfully entering new therapeutic areas could drive substantial revenue growth for BioDelivery Sciences over the next 3-5 years.
- Strategic partnerships and collaborations: Partnering with larger pharmaceutical companies or research institutions can provide BioDelivery Sciences with access to additional resources, expertise, and distribution channels. Collaborations can also accelerate the development and commercialization of new products. The pharmaceutical industry is characterized by a high degree of collaboration, with companies often partnering to share risks and rewards. Securing strategic partnerships could enhance BioDelivery Sciences' competitive position and drive long-term growth.
- Successful commercialization of existing products: Driving increased sales and market share for its existing products is a key growth opportunity for BioDelivery Sciences. This can be achieved through targeted marketing campaigns, expansion of the sales force, and improved patient access. The company's products address unmet needs in pain management and other specialty areas, providing a strong foundation for growth. Successfully commercializing its products could generate significant revenue and profitability for BioDelivery Sciences in the near term.
- Development of new pipeline assets: Investing in research and development to create new products is essential for long-term growth in the pharmaceutical industry. BioDelivery Sciences can leverage its expertise in drug delivery to develop innovative formulations and therapies. A strong pipeline of new products can drive future revenue growth and enhance the company's competitive position. The pharmaceutical industry is highly innovative, with companies constantly seeking to develop new and improved treatments. Successfully developing new pipeline assets could create significant value for BioDelivery Sciences over the long term.
- Geographic expansion: Expanding into new geographic markets can provide BioDelivery Sciences with access to a larger customer base and increased revenue opportunities. This can be achieved through partnerships with local distributors or by establishing a direct presence in key markets. The global pharmaceuticals market is vast and diverse, with significant growth potential in emerging markets. Successfully expanding its geographic reach could drive substantial revenue growth for BioDelivery Sciences over the next 5-10 years.
What Threats Does BDSIW Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and patent expirations.
- Changes in healthcare reimbursement policies.
- Product liability claims.
What Are BDSIW's Competitive Advantages?
- Proprietary drug delivery technologies create a barrier to entry.
- Patents protect key products and formulations.
- Strong relationships with physicians and pharmacies.
- Expertise in developing and commercializing specialty pharmaceuticals.
What Does BDSIW Do?
BioDelivery Sciences Intl, Inc. Wrrt is a specialty pharmaceutical company focused on developing and commercializing innovative products for chronic conditions. While specific details regarding its founding story are not available, the company has evolved to focus on utilizing its drug delivery technologies to create differentiated products. Their primary focus is on addressing unmet needs in pain management and other specialty areas. BioDelivery Sciences leverages its expertise in drug delivery to improve the therapeutic benefits and patient experience of existing medications. The company's geographic reach is primarily within the United States, where it markets and distributes its products. BioDelivery Sciences competes with other pharmaceutical companies, both large and small, that develop and market products for similar indications. However, they differentiate themselves through their focus on innovative drug delivery and patient-centric formulations. The company aims to build a sustainable business by developing and commercializing products that offer improved efficacy, safety, and convenience for patients.
What Products and Services Does BDSIW Offer?
- Develop innovative drug delivery technologies.
- Formulate and manufacture specialty pharmaceutical products.
- Focus on addressing unmet needs in pain management.
- Commercialize and market pharmaceutical products.
- Seek partnerships for research and development.
- Improve therapeutic benefits and patient experience of existing medications.
How Does BDSIW Make Money?
- Develop and patent novel drug formulations and delivery systems.
- Manufacture and sell proprietary pharmaceutical products.
- Generate revenue through direct sales and distribution.
- Collaborate with other pharmaceutical companies for licensing and co-development agreements.
What Industry Does BDSIW Operate In?
BioDelivery Sciences Intl, Inc. Wrrt operates within the drug manufacturing industry, a sector characterized by intense competition, high regulatory hurdles, and significant research and development costs. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. BioDelivery Sciences competes with both large pharmaceutical companies and smaller specialty players. The company's focus on innovative drug delivery technologies allows it to carve out a niche within the broader market.
Who Are BDSIW's Key Customers?
- Patients suffering from chronic pain and other conditions.
- Physicians who prescribe medications.
- Pharmacies that dispense medications.
- Hospitals and clinics.
Key Financial Metrics
Return on equity for BioDelivery Sciences Intl, Inc. Wrrt stands at -30.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.4%, showing how much profit it generates from its asset base. A current ratio of 2.18 indicates the company holds enough short-term assets to cover its near-term obligations.
Insider Activity
The most recent 12 insider filings for BioDelivery Sciences Intl, Inc. Wrrt break down as 12 sales and 0 purchases. On net that is roughly 1.2M shares disposed (about $2.9M), a signal worth weighing alongside the fundamentals.
BDSIW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Community sentiment has turned increasingly positive, with discussions highlighting the potential of their product pipeline.
- Analysts have noted improvements in operational efficiency, which could lead to better margins and profitability in the coming quarters.
- Market perception is shifting as the company is gaining recognition for its innovative approaches in the pharmaceutical space.
Bear Case
- Concerns about regulatory hurdles remain prevalent in community discussions, with some fearing potential delays in product approvals.
- Recent earnings reports have shown mixed results, leading to skepticism about the company's ability to meet growth expectations.
- Community sentiment has also noted the competitive landscape, with increased pressure from rival companies that could impact market share.
- Insider selling activity, although not significant, has raised some eyebrows and led to questions about management's outlook on future performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BDSIW Latest News
No recent news available for BDSIW.
BioDelivery Sciences Intl, Inc. Wrrt Healthcare Stock: Key Questions Answered
What happened to BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) stock?
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW) no longer trades on public markets. It was delisted in March 2022. The figures below are historical and are not a current quote.
Can I still buy BDSIW shares?
No. BDSIW stopped trading on public markets in March 2022, so the shares are not available through a broker. Anything you see quoted for BDSIW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BDSIW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to BioDelivery Sciences Intl, Inc. Wrrt. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does BioDelivery Sciences Intl, Inc. Wrrt do?
BioDelivery Sciences Intl, Inc. Wrrt is a specialty pharmaceutical company that develops and commercializes innovative products, primarily focused on pain management and other specialty areas. They utilize advanced drug delivery technologies to improve the therapeutic benefits and patient experience of existing medications. The company's business model centers around creating differentiated products that address unmet needs in the market, generating revenue through direct sales and strategic partnerships within the pharmaceutical industry.
What are the main revenue streams for BioDelivery Sciences Intl, Inc. Wrrt?
BioDelivery Sciences Intl, Inc. Wrrt generates revenue primarily through the sale of its proprietary pharmaceutical products. These products target specific therapeutic areas, such as pain management. Revenue streams are directly tied to prescription volume, market access, and reimbursement rates. The company also explores potential revenue through licensing agreements and partnerships with other pharmaceutical companies, expanding their reach and leveraging their drug delivery technologies.
What are the main risks for BDSIW?
BioDelivery Sciences Intl, Inc. Wrrt faces several risks inherent to the pharmaceutical industry. These include the potential failure of clinical trials, regulatory hurdles in obtaining drug approvals, and competition from both generic and branded products. Additionally, the company's high beta indicates significant market volatility, which could impact investor returns. Product liability claims and changes in healthcare reimbursement policies also pose potential risks to the company's financial performance.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for BDSIW. Information is limited to available financial data and company overview.